Pharmacokinetic/pharmacodynamic (PK/PD) relationships for the angiogenesis inhibitor ABT-510 in preclinical efficacy models

被引：0
|
作者：
Carr, R
Marsh, K
Schneider, A
Henkin, J
Wang, Y
Joseph, I
Khanna, C
Humerickhouse, R
机构：
来源：
EUROPEAN JOURNAL OF CANCER | 2002年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
250
引用
收藏
页码：S79 / S79
页数：1
相关论文
共 50 条
  • [31] Preclinical pharmacokinetic (PK)/pharmacodynamic (PD)/Efficacy modeling for MLN2480, an investigational pan-RAF kinase inhibitor, in A375 and SKMEL-2 human melanoma xenografts
    Patel, M.
    Chouitar, J.
    Mettetal, J.
    Gangolli, E.
    Balani, S.
    Shimoga, P.
    Galvin, K.
    Shyu, W. C.
    Chakravarty, A.
    Zopf, C. J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 161 - 161
  • [32] QUANTITATIVE STRUCTURE-PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) PROPERTIES-RELATIONSHIPS (QSPR) FOR NEUROMUSCULAR BLOCKERS (NMB)
    Gottipati, G.
    Venitz, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S22 - S22
  • [33] Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PF-00337210, a highly selective VEGFR inhibitor
    Liu, G.
    LoRusso, P. M.
    Goncalves, P.
    Holen, K.
    Traynor, A.
    Zhang, J.
    Hee, B.
    Tortorici, M.
    Shalinsky, D. R.
    Ricart, A. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] Vicriviroc Is a Novel, Potent CCR5 Inhibitor With Outstanding Pharmaceutic, Pharmacokinetic and PharmaCodynamic (PK/PD) Properties
    Lisa Dunkle
    Anther Keung
    Angela Sansone
    Julie Strizki
    Retrovirology, 2
  • [35] A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of the selective aurora kinase inhibitor GSK1070916A.
    McNeish, Iain
    Anthoney, Alan
    Loadman, Paul
    Berney, Dan
    Joel, Simon
    Halford, Sarah E. R.
    Buxton, Emily
    Race, Amanda
    Ikram, Mohammed
    Scarsbrook, Andrew
    Patikis, Angela
    Rockall, Andrea
    Dobbs, Nicola A.
    Twelves, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] Vicriviroc is a novel, potent CCR5 inhibitor with outstanding pharmaceutic, pharmacokinetic and PharmaCodynamic (PK/PD) properties
    Dunkle, Lisa
    Keung, Anther
    Sansone, Angela
    Strizki, Julie
    RETROVIROLOGY, 2005, 2 (Suppl 1)
  • [37] Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of LBH589A: A novel histone deacetylase inhibitor
    Beck, J
    Fischer, T
    Rowinsky, E
    Huber, C
    Mita, M
    Atadja, P
    Peng, B
    Kwong, C
    Dugan, M
    Patnaik, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 201S - 201S
  • [38] Current status and future perspective on preclinical pharmacokinetic and pharmacodynamic (PK/PD) analysis: Survey in Japan pharmaceutical manufacturers association (JPMA)
    Goto, Akihiko
    Abe, Sadahiro
    Koshiba, Shoko
    Yamaguchi, Koji
    Sato, Nobuo
    Kurahashi, Yoshikazu
    DRUG METABOLISM AND PHARMACOKINETICS, 2019, 34 (02) : 148 - 154
  • [39] Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models
    Jasmine, Sumer
    Mandl, Adel
    Krueger, Timothy E. G.
    Dalrymple, Susan L.
    Antony, Lizamma
    Dias, Jennifer
    Celatka, Cassandra A.
    Tapper, Amy E.
    Kleppe, Maria
    Kanayama, Mayuko
    Jing, Yuezhou
    Speranzini, Valentina
    Wang, Yuzhuo Z.
    Luo, Jun
    Trock, Bruce J.
    Denmeade, Samuel R.
    Carducci, Michael A.
    Mattevi, Andrea
    Rienhoff Jr, Hugh Y.
    Isaacs, John T.
    Brennen, W. Nathaniel
    PROSTATE, 2024, 84 (10): : 909 - 921
  • [40] Semi-physiological pharmacokinetic-pharmacodynamic (PK/PD) models for troxacitabine-induced neutropenia and thrombocytopenia
    Ng, C. M.
    Muralidhar, B.
    Takimoto, C. H.
    Lin, C.
    Patnaik, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345